Enlicitide vs Laroprovstat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Enlicitide · Lipfendra
Marketed by Merck & Co.
NCT05952856 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled Phase 3 trial in 2,909 adults with hypercholesterolemia. The primary endpoint was the mean percent change in LDL-C from baseline to Week 24, a standard regulator-accepted efficacy measure for lipid-lowering therapy. The active arm achieved a significantly greater LDL-C reduction than placebo (-57.1% vs +3.0%, p<0.001), so the trial met its primary endpoint with a large effect size and low risk of bias.
Next expected readout: November 2027 · NCT07821944 (registry estimate)
Reported efficacy
Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24); Number of Participants With One or More Adverse Events (AEs) (Up to 60 weeks); Number of Participants Who Discontinued Study Drug Due to an AE (Up to 52 weeks): Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001). (met)
Result source: NCT05952856
Laroprovstat
Developed by AstraZeneca
NCT06173570 · Phase 2 · completed
The study randomized 428 participants to four AZD0780 dose groups or matched placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the regulator-accepted lipid measure LDL cholesterol, and all four AZD0780-versus-placebo comparisons were statistically significant in the favorable direction (p<0.001).
Next expected readout: January 2027 · NCT07000136 (registry estimate)
Reported efficacy
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo) (met)
Result source: NCT06173570
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Enlicitide | Laroprovstat |
|---|---|---|
| LDL-C, % change | -58.2% vs 2.6%−60.8 vs placeboNCT059528696 other results
| -46.6% vs 4.1%−50.7 vs placeboNCT061735707 other results
|
| Non-HDL-C, % change | -52.3% vs 2.1%−54.4 vs placeboNCT059528695 other results
| -41.6% vs 3.5%−45.2 vs placeboNCT061735707 other results
|
| ApoB, % change | -48.2% vs 1.8%−50 vs placeboNCT059528695 other results
| -37.0% vs 2.9%−39.9 vs placeboNCT061735707 other results
|
| Lp(a), % change | -24.7% vs -1.6%−23.1 vs placeboNCT059528691 other result
| -19.4% vs 0%−19.4 vs placeboNCT061735703 other results
|
| 3-point MACE (% with event) | —Not posted · NCT07216482 | —Trial running · NCT06834932 |
LDL-C, % change
- Enlicitide
- -58.2% vs 2.6%−60.8 vs placeboNCT05952869
6 other results
- -64.6% vs -36.5% NCT06450366
- -55.3% vs 8.7% NCT05952869
- -59.7% vs 1.2% NCT05261126
- -57.9% vs 1.2% NCT05261126
- -54.5% vs 1.2% NCT05261126
- -40% vs 1.2% NCT05261126
- Laroprovstat
- -46.6% vs 4.1%−50.7 vs placeboNCT06173570
7 other results
- -41.1% vs 4.1% NCT06173570
- -33.8% vs 4.1% NCT06173570
- -31.2% vs 4.1% NCT06173570
- -46.4% vs 3.4% NCT06173570
- -40.5% vs 3.4% NCT06173570
- -33.4% vs 3.4% NCT06173570
- -30.5% vs 3.4% NCT06173570
Non-HDL-C, % change
- Enlicitide
- -52.3% vs 2.1%−54.4 vs placeboNCT05952869
5 other results
- -58% vs -31.8% NCT06450366
- -54.3% vs 1.5% NCT05261126
- -51.8% vs 1.5% NCT05261126
- -49% vs 1.5% NCT05261126
- -34.4% vs 1.5% NCT05261126
- Laroprovstat
- -41.6% vs 3.5%−45.2 vs placeboNCT06173570
7 other results
- -41.4% vs 2.9% NCT06173570
- -35.1% vs 3.5% NCT06173570
- -34.8% vs 2.9% NCT06173570
- -29.9% vs 3.5% NCT06173570
- -29.4% vs 2.9% NCT06173570
- -26.9% vs 3.5% NCT06173570
- -26.1% vs 2.9% NCT06173570
ApoB, % change
- Enlicitide
- -48.2% vs 1.8%−50 vs placeboNCT05952869
5 other results
- -54.6% vs -27.7% NCT06450366
- -51.8% vs 0% NCT05261126
- -48.7% vs 0% NCT05261126
- -45.8% vs 0% NCT05261126
- -32.8% vs 0% NCT05261126
- Laroprovstat
- -37.0% vs 2.9%−39.9 vs placeboNCT06173570
7 other results
- -36.9% vs 2.4% NCT06173570
- -34.3% vs 2.9% NCT06173570
- -33.9% vs 2.4% NCT06173570
- -25.4% vs 2.9% NCT06173570
- -24.5% vs 2.4% NCT06173570
- -24.1% vs 2.9% NCT06173570
- -23.4% vs 2.4% NCT06173570
Lp(a), % change
- Enlicitide
- -24.7% vs -1.6%−23.1 vs placeboNCT05952869
1 other result
- -26.2% vs 10.4% NCT06450366
- Laroprovstat
- -19.4% vs 0%−19.4 vs placeboNCT06173570
3 other results
- -19.6% vs 0% NCT06173570
- -11.2% vs 0% NCT06173570
- -7.5% vs 0% NCT06173570
3-point MACE (% with event)
- Enlicitide
- —Not posted · NCT07216482
- Laroprovstat
- —Trial running · NCT06834932
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Enlicitide: 3 of 4 rows · Laroprovstat: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Enlicitide | Laroprovstat |
|---|---|---|
| Dropout rate | —20 mga NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 11 more results3% NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —20 mg NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 1%Enlicitide NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2.6%30 mg NCT05261126 · Phase 2 · registry result, not featured evidence 2.6%18 mg NCT05261126 · Phase 2 · registry result, not featured evidence 0%12 mg NCT05261126 · Phase 2 · registry result, not featured evidence 2.6%6 mg NCT05261126 · Phase 2 · registry result, not featured evidence 0%Panel A: Moderate Renal Impairment NCT05934292 · Phase 1 · registry result, not featured evidence 0%Panel B: Severe RI NCT05934292 · Phase 1 · registry result, not featured evidence 11.1%Panel C: End-Stage Renal Disease ( NCT05934292 · Phase 1 · registry result, not featured evidence 0%Panel D: Healthy Controls NCT05934292 · Phase 1 · registry result, not featured evidence | 5.9%30 mgb NCT06173570 · Phase 2 show 3 more results1.2%10 mg NCT06173570 · Phase 2 4.7%3 mg NCT06173570 · Phase 2 5.8%1 mg NCT06173570 · Phase 2 |
| Discontinued due to AEs | —20 mga NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 11 more results— NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —20 mg NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 —Enlicitide NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —30 mg NCT05261126 · Phase 2 · registry result, not featured evidence —18 mg NCT05261126 · Phase 2 · registry result, not featured evidence —12 mg NCT05261126 · Phase 2 · registry result, not featured evidence —6 mg NCT05261126 · Phase 2 · registry result, not featured evidence —Panel A: Moderate Renal Impairment NCT05934292 · Phase 1 · registry result, not featured evidence —Panel B: Severe RI NCT05934292 · Phase 1 · registry result, not featured evidence —Panel C: End-Stage Renal Disease ( NCT05934292 · Phase 1 · registry result, not featured evidence —Panel D: Healthy Controls NCT05934292 · Phase 1 · registry result, not featured evidence | 2.4%30 mgb NCT06173570 · Phase 2 show 3 more results0%10 mg NCT06173570 · Phase 2 0%3 mg NCT06173570 · Phase 2 1.2%1 mg NCT06173570 · Phase 2 |
| Serious AEs | 9.9%20 mga NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 11 more results4.5% NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 0%20 mg NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 —Enlicitide NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2.6%30 mg NCT05261126 · Phase 2 · registry result, not featured evidence 2.6%18 mg NCT05261126 · Phase 2 · registry result, not featured evidence 3.9%12 mg NCT05261126 · Phase 2 · registry result, not featured evidence 1.3%6 mg NCT05261126 · Phase 2 · registry result, not featured evidence 0%Panel A: Moderate Renal Impairment NCT05934292 · Phase 1 · registry result, not featured evidence 0%Panel B: Severe RI NCT05934292 · Phase 1 · registry result, not featured evidence 11.1%Panel C: End-Stage Renal Disease ( NCT05934292 · Phase 1 · registry result, not featured evidence 0%Panel D: Healthy Controls NCT05934292 · Phase 1 · registry result, not featured evidence | 1.2%30 mgb NCT06173570 · Phase 2 show 3 more results2.4%10 mg NCT06173570 · Phase 2 2.4%3 mg NCT06173570 · Phase 2 2.3%1 mg NCT06173570 · Phase 2 |
| Most frequent reported AEs | a nasopharyngitis 9.4% (placebo 7.9%) influenza 8.4% (placebo 8.9%) accidental overdose 7.9% (placebo 4%) NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 9 more results30 mg covid-19 5.3% (placebo 9.3%) arthralgia 2.6% (placebo 1.3%) nausea 2.6% (placebo 0%) NCT05261126 · Phase 2 · registry result, not featured evidence 18 mg covid-19 6.6% (placebo 9.3%) nausea 5.3% (placebo 0%) diarrhoea 3.9% (placebo 1.3%) NCT05261126 · Phase 2 · registry result, not featured evidence 12 mg dyspepsia 6.6% (placebo 1.3%) arthralgia 5.3% (placebo 1.3%) fatigue 3.9% (placebo 6.7%) NCT05261126 · Phase 2 · registry result, not featured evidence 6 mg covid-19 7.8% (placebo 9.3%) diarrhoea 6.5% (placebo 1.3%) dyspepsia 1.3% (placebo 1.3%) NCT05261126 · Phase 2 · registry result, not featured evidence dry mouth 12.5% hypertension 12.5% animal bite 0% NCT05934292 · Phase 1 · registry result, not featured evidence animal bite 12.5% orthostatic hypotension 12.5% dry mouth 0% NCT05934292 · Phase 1 · registry result, not featured evidence animal bite 0% dry mouth 0% hypertension 0% NCT05934292 · Phase 1 · registry result, not featured evidence animal bite 0% dry mouth 0% hypertension 0% NCT05934292 · Phase 1 · registry result, not featured evidence | show 3 more results |
Notes
- aPopulation comparability has not been reviewed for 8 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Enlicitide
show 1 more result
show 1 more result
show 3 more results
Laroprovstat
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enlicitide's landscape · Laroprovstat's landscape